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     Ataxia-telangiectasia is a rare disorder with neurological manifestations, caused by mutations in ATM 
gene. This gene produces a serine/threonine protein kinase, an activator of the DNA damage response in the 
face of DNA DSBs, which phosphorylates downstream substrates, integrating with DNA repair procedure. 
Most ATM mutations are private mutations and, there are no mutational hotspots in the ATM gene. This 
study tries to unveil a new mutation in this gene in an 8 years old A-T patient. This mutation led to 
fundamental alterations in ATM protein structure and representation of AT.  
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INTRODUCTION 
     Ataxia-telangiectasia (AT, OMIM#208900) 
also named Louis-Bar Syndrome is an infrequent 
autosomal recessive disorder characterized by 
progressive neurological degeneration, ocular and 
skin related telangiectasia[1], cerebellar ataxia, 
immune deficiency[1-3], and a predisposition to 
malignancies[3]. AT is the most common cause of 
progressive cerebellar ataxia in infants in which 
chromosome breakage is quite common[4]. 
Cellules of such patients are sensitive to killing by 
ionizing radiation (IR)[5], and their 
lymphoblastoid cells are abnormally persistent to 
inhibition of DNA synthesis in response to 
ionizing radiation[6]. The recent feature utilizes 
for classification of different complementation 
groups of the disease[2]. Since 1995, when the 
defective gene in AT was discovered [7], several 
mutations have been discovered in the ATM gene, 
resulting in ataxia telangiectasia [8-10]. At least 4 
of these groups (A, C, D, and E) are mapped to 
chromosome 11q23[11] and are accompanied  
with mutations in ATM gene. ATM, a 370kDa  
serine/threonine protein kinase[12], is a pioneer 
activator of the DNA (DSBs). ATM 
phosphorylates downstream substrates which are 
involved in DNA repair and administration of cell 
cycle [13]. However, recent pieces of evidence 
show the case of involvement of ATM protein 
epigenetic regulation [14]. On the other hand, 
epigenetic silencing of ATM is reported in 
different cancers like breast cancer and this 
molecule is an epimarker[15]. Epigenetic 
silencing or dysregulation has been evidenced to 
be important in many human diseases like 
infertility or breast cancer [16]. Epidrug therapies 
for these genes, such as ATM might prove to be 
promising in future treatment options. Then, 
knowing different pathogenic mechanisms and  
 




mutations in ATM seems undeniable [17-19].  
Most ATM mutations are private mutations and 
there are no mutational hotspots in ATM gene. 
This study reports an Iranian patient enduring AT 
who was found to be homozygous for a novel 
single base pair deletion in ATM gene. 
 
CASE REPORT 
     One female patient with chief compliment of 
ataxia and recurrent infections was referred to 
Sarem Medical Genetics Laboratory for genetic 
counselling and mutation detection. 
Clinical findings  
     An 8 year old female patient who is clinically 
considered for progressive ataxia, vertigo and 
tremor since age 30th month is the case of the 
present study. The patient is mentally normal and 
has been suffering from recurrent diarrheal and 
respiratory infections for years. Her parents were 
healthy persons who had a consanguineous ethnic 
Iranian marriage (pedigree is shown in figure 1A). 
Dystonic cerebral palsy was diagnosed at first 2-3 
years of her life and she was considered for 
unsteady gait and frequent falls since the age of 3. 
At first, ataxic walking was diagnosed at the age 
of 30 months, and then it remained stable, became 
progressive, leading to loss of walking ability in 
referring time. She suffered from delayed slurred 
speech movement patterns for many years, 
demonstrating ataxia. Investigations revealed low 
lymphocyte count and IgA while Alpha-
fetoprotein (AFP) testing was not available. The 
child received symptomatic and supportive 
treatments for recurrent infections. Bilateral 
ocular telangiectasia and ocular-motor apraxia 
was present at the age of 7 years. Neurologic 
symptoms were progressive in recent two years, 
conveyed by involuntary movements of the lips 
and tremor in superior limbs. All clinical findings 
supposed the proband to be affected by ataxia 
telangiectasia; she then was evaluated for 
pathogenic variations in her ATM gene. 
 
 
Figure 1. A) Female patient who was born in a consanguineous marriage. B) Sanger sequencing of targeted region to detect the 
mutation in homozygous state. 
 
Molecular genetic assays 
     Family members received genetic counseling 
and they were aware about the study. Informed 
consent obtained from patient’s parents indicating 
their satisfaction to be a participant in this study. 
The genomic DNA was isolated from peripheral 
blood leukocytes of all family members using 
DNA purification kit (Roche, Switzerland). 
Extracted DNA was used to perform targeted 
gene capture using a custom capture kit 
(QIAGEN, Germany). The libraries were 
sequenced to mean >80-100X coverage on 
Illumina sequencing platform (Illumina, San 
Diego, CA, USA). The obtained sequences were 
aligned to the GRCh37/hg19 human reference 
genome using BWA program[20, 21] and 
analyzed using Picard and GATK-Lite toolkit [22, 
23] was used to identify variants in the targeted 
genes relevant to clinical indication. Annotation 
of the variant was performed against the 




Ensemble release 75 gene model 
(http://www.ensembl.org/index.html). Clinically 
relevant mutations were annotated using 
published variants in literatures and a set of 





international.com/product/hgmd) and SwissVar 
(http://swissvar.expasy.org/). Using best 
recommendations, only pathogenic variants were 
extracted and common variants registered in 




excluded. The pathogenic effects of all candidate 
variants were predicted using SIFT 
(http://sift.jcvi.org), Polyphen2 
(http://genetics.bwh.harvard.edu/pph2/) and 
Mutation Taster (http://www.mutationtaster.org/) 
software. Segregation analysis was performed to 
confirm the mutation inheritance through parents 
and interpretation of unveiled mutation. 
Moreover, candidate variants were validated in all 
family members by Sanger sequencing.  
Molecular genetic findings             Diagnosis was 
confirmed by the identification of a novel deletion 
in the ATM gene in studied patient. A 
homozygous single base pair deletion in exon 43 
of the ATM gene (chr11:108188201delC) 
resulting in a frameshift and premature 
termination of the protein 19 amino acids 
downstream to codon 2101 
(p.Gln2101LysfsTer19:ENST00000278616) was 
detected. Ataxia telangiectasia (OMIM#208900) 
is caused by homozygous or compound 
heterozygous mutations in the ATM gene 
(OMIM*607585). This novel variant was not 
reported in both the 1000 genomes and ExAC 
databases (Figure 2). The region is conserved 
across some vertebrates (Figure 3) representing its 
importance. This variant was not registered in 
house database, 1000 Genomes database, and 
NHLBI Exome Sequencing Project (ESP6500). 
The followed Sanger sequencing revealed the 
presence of this mutation in proband (Figure 1B). 
 
 
Figure 2. The variant was not found in ExAC Browser Beta. 





Figure 3. Region chr11:108188195-108188205 in ATM gene. A) The mentioned position in ATM gene is conserved across most 
vertebrates. B) The arrow pinpoints to the position of deletion. 
 
DISCUSSION 
     Incidence of AT among patients with primary 
immune deficiency disorders is high in Iran, 
probably due to prevalence of consanguineous 
marriage [24]. Based on declared indications, this 
ATM variation is classified as a possibly 
noteworthy variant and has to be carefully 
correlated with the clinical symptoms. The 
reported mutation led to frameshifting, Nonsense 
Mediated Decay (NMD) and Ataxia 
Telangiectasia through affecting structure of 
ATM protein in the end (supplementary Figure). 
Referring to Multiz alignment of 100 vertebrates, 
the base which is deleted in the patient is 
conserved between human, rhesus and dog 
(Figure 3), demonstrating the importance of this 
position and catastrophic consequences of 
deletion in this region. 
 
 
Figure 4. Supplementary Figure.A) Normal ATM protein. B) Mutated ATM protein. (The mutated protein was not probably 











In spite of rarity of AT disease, heterozygous 
mutations in ATM gene occur at 1% of general 
population [7] then discovering new mutations in 
this gene can improve quality of diagnostic tests 
and health in general population.  
ATM protein has four conserved domains which 
are critical for its function. 75% of these 
conserved domains span through amino acid 
number 2097 to 3056 
(http://www.ncbi.nlm.nih.gov/Structure/cdd/wrps
b.cgi?INPUT_TYPE=live&SEQUENCE=AAB65
827.1). Our declared mutation in ATM protein 
deranges NMD and production of truncated 
protein. Regarding the position of discovered 
mutation and termination of its translation after 19 
amino acids, this truncated ATM has no 
conserved PIKKc_ATM (accession:cd05171), 
FATC (accession: pfam02260), and FAT 
(accession pfam02259) domains(supplementary 
Figure 1). Complete lack of ATP binding site, 
catalytic loop, activation loop [25], and FAT 
[26]domains conclude malfunctioning of the 
truncated ATM protein where Ataxia 
Telangiectasia is a probable consequence. 
Moreover, the mutated protein was not probably 
synthesized due to NMD mechanism. 
The findings are contextulalixed, where this 
mutation interpreted as a pathogenic mutation that 
causes AT in the patient. Every patient with a 
suspicion of AT needs to be genetically tested and 
the pathogenic variant needs to be found for 
future guidance in the family and the patient. This 
novel mutation should be considered for PND in 
future pregnancies and upcoming managements of 
such families. As the newly-found mutation is a 
truncating mutation that disrupts the protein and 
eliminates most parts of the protein and its 
important functional domains, the pathogenicity 
does not need be confirmed through functional 
studies. The proband and her parents should have 
a standard genetic counseling for future 
pregnancies. PND, based on direct and indirect 
methods to ensure the absence of aforementioned 
mutation and affected allele of the family is 
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